MIRA INFORM REPORT

 

 

Report Date :

20.09.2013

 

IDENTIFICATION DETAILS

 

Name :

IDIS LTD.  

 

 

Registered Office :

Idis House Churchfield Road, Weybridge, KT13 8DB

 

 

Country :

United Kingdom

 

 

Financials (as on) :

30.11.2012

 

 

Date of Incorporation :

29.06.1987

 

 

Com. Reg. No.:

02143039

 

 

Legal Form :

Private Subsidiary Company

 

 

Line of Business :

Subject is engaged in the field of named-patient medicine sourcing and supply service

 

 

No. of Employees :

180

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory 

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

United Kingdom

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 


 

 

United Kingdom ECONOMIC OVERVIEW

 

The UK, a leading trading power and financial center, is the second largest economy in Europe after Germany. Over the past two decades, the government has greatly reduced public ownership and contained the growth of social welfare programs. Agriculture is intensive, highly mechanized, and efficient by European standards, producing about 60% of food needs with less than 2% of the labor force. The UK has large coal, natural gas, and oil resources, but its oil and natural gas reserves are declining and the UK became a net importer of energy in 2005. Services, particularly banking, insurance, and business services, account by far for the largest proportion of GDP while industry continues to decline in importance. After emerging from recession in 1992, Britain's economy enjoyed the longest period of expansion on record during which time growth outpaced most of Western Europe. In 2008, however, the global financial crisis hit the economy particularly hard, due to the importance of its financial sector. Sharply declining home prices, high consumer debt, and the global economic slowdown compounded Britain's economic problems, pushing the economy into recession in the latter half of 2008 and prompting the then BROWN (Labour) government to implement a number of measures to stimulate the economy and stabilize the financial markets; these include nationalizing parts of the banking system, temporarily cutting taxes, suspending public sector borrowing rules, and moving forward public spending on capital projects. Facing burgeoning public deficits and debt levels, in 2010 the CAMERON-led coalition government (between Conservatives and Liberal Democrats) initiated a five-year austerity program, which aimed to lower London's budget deficit from over 10% of GDP in 2010 to nearly 1% by 2015. In November 2011, Chancellor of the Exchequer George OSBORNE announced additional austerity measures through 2017 because of slower-than-expected economic growth and the impact of the euro-zone debt crisis. The CAMERON government raised the value added tax from 17.5% to 20% in 2011. It has pledged to reduce the corporation tax rate to 21% by 2014. The Bank of England (BoE) implemented an asset purchase program of up to £375 billion (approximately $605 billion) as of December 2012. During times of economic crisis, the BoE coordinates interest rate moves with the European Central Bank, but Britain remains outside the European Economic and Monetary Union (EMU). In 2012, weak consumer spending and subdued business investment weighed on the economy. GDP fell 0.1%, and the budget deficit remained stubbornly high at 7.7% of GDP. Public debt continued to increase.

 

Source : CIA

 

 


Company name & address

 

Idis Ltd. 

Idis House Churchfield Road

Weybridge, KT13 8DB

United Kingdom

 

Tel:       01932824000

Fax:      01932824200

 

Web:    www.idispharma.com

           

 

Synthesis

 

Employees:                 180

Company Type:            Private Subsidiary

Corporate Family:          46 Companies

Ultimate Parent:             Cbpe Capital LLP

Quoted Status:             Non-quoted Company

Incorporation Date:        29-Jun-1987

Auditor:                                   Deloitte LLP     

Financials in:                 USD (Millions)

Fiscal Year End:            30-Nov-2012

Reporting Currency:       British Pound Sterling

Annual Sales:               228.6  1

Net Income:                 0.3

Total Assets:                 130.4

 

 

Business Description     

 

IDIS Ltd. is one of the world’s leading authorities in the field of named-patient medicine sourcing and supply services. The company works in partnership with the pharmaceutical and biotechnology industries to establish and deliver prelaunch named-patient management programmes. It sources and supplies medicines for clinical trials, develops solutions for discontinued brands and manages temporary supply problems. The company holds in-house teams that provide expertise in legal and regulatory requirements, distribution and storage, technical and clinical support, import requirements and export requirements. IDIS Ltd., incorporated in 1987, maintains its head offices in Surbiton, Surrey. (Updated by OneSource Information Services)

 

Industry            

Industry           Health and Personal Care Wholesale

ANZSIC 2006:   3720 - Pharmaceutical and Toiletry Goods Wholesaling

ISIC Rev 4:        4649 - Wholesale of other household goods

NACE Rev 2:     4646 - Wholesale of pharmaceutical goods

NAICS 2012:     424210 - Drugs and Druggists' Sundries Merchant Wholesalers

UK SIC 2007:    4646 - Wholesale of pharmaceutical goods

US SIC 1987:    5122 - Drugs, Drug Proprietaries, and Druggists' Sundries

 

Key Executives   

             

 

Name

Title

Natalie Douglas

Chief Executive Officer

Richard Greatorex

Divisional Marketing Director

Emma Grant

Head of Customer Services

Guy Strutton

Global Head of Learning and Development

Suzanne Gagnon

CHIEF MEDICAL OFFICER; member of the leadership team

 

 

Financial Summary    

 

 

FYE: 30-Nov-2012

USD (mil)

Key Figures

 

Current Assets

122.66

Fixed Assets

7.72

Total Liabilities

90.55

Net Worth

39.83

 

Key Ratios

 

Current Ratio

1.35

Acid Test

1.28

 

1 - Profit & Loss Item Exchange Rate: USD 1 = GBP 0.6329453

2 - Balance Sheet Item Exchange Rate: USD 1 = GBP 0.6241056

 

 

Corporate Overview

 

Location

Idis House Churchfield Road

Weybridge, KT13 8DB

Surrey County

United Kingdom

Tel:       01932824000

Fax:      01932824200

Web:    www.idispharma.com

           

Sales GBP(mil):             144.7

Assets GBP(mil):           81.4

Employees:                  180

Fiscal Year End:            30-Nov-2012

Industry:                       Personal and Household Products

           

Registered Address:

Idis House Churchfield Road

Weybridge, KT13 8DB

United Kingdom

 

Incorporation Date:        29-Jun-1987

Company Type:             Private Subsidiary

Quoted Status:              Not Quoted

Registered No.(UK):      02143039

Chief Executive Officer: Natalie Douglas

 

Industry Codes

ANZSIC 2006 Codes:

3720     -          Pharmaceutical and Toiletry Goods Wholesaling

 

ISIC Rev 4 Codes:

4649     -          Wholesale of other household goods

 

NACE Rev 2 Codes:

4646     -          Wholesale of pharmaceutical goods

 

NAICS 2012 Codes:

424210  -          Drugs and Druggists' Sundries Merchant Wholesalers

 

US SIC 1987:

5122     -          Drugs, Drug Proprietaries, and Druggists' Sundries

 

UK SIC 2007:

4646     -          Wholesale of pharmaceutical goods

 

Business Description

IDIS Ltd. is one of the world’s leading authorities in the field of named-patient medicine sourcing and supply services. The company works in partnership with the pharmaceutical and biotechnology industries to establish and deliver prelaunch named-patient management programmes. It sources and supplies medicines for clinical trials, develops solutions for discontinued brands and manages temporary supply problems. The company holds in-house teams that provide expertise in legal and regulatory requirements, distribution and storage, technical and clinical support, import requirements and export requirements. IDIS Ltd., incorporated in 1987, maintains its head offices in Surbiton, Surrey. (Updated by OneSource Information Services)

 

More Business Descriptions

The sourcing and supply of medicines on a named-patient basis, the supply of drugs for clinical trials and the provision of alternatives when medicines are in short supply.

 

The sourcing and supply of medicines on a named-patient basis, the supply of drugs for clinical trial

 

Chemists - Wholesale

 

Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. Idis is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients. Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world. Leadership Team Our leadership team is united by a strong set of values and beliefs, and a commitment to help the lives of patients with unmet medical needs around the world. We joined Idis to become... read more Our Journey Idis was founded in the UK in 1987 to search for medicines that were not available on the UK market for individual patients. Idis pioneered... read more Code of Ethics The Idis Code of Ethics defines the practices, behaviors and standards we are committed to in running our business. These ensure we interact...

 

Financial Data

Financials in:

GBP(mil)

 

Revenue:

144.7

Net Income:

0.2

Assets:

81.4

Current Assets:

76.6

 

Fixed Assets:

4.8

 

Long Term Debt:

0.0

 

Total Liabilities:

56.5

 

Issued Capital:

0.3

 

Working Capital:

20.0

 

Net Worth:

24.9

 

 

 

Date of Financial Data:

30-Nov-2012

 

1 Year Growth

11.7%

NA

NA

Key Corporate Relationships

Auditor:

Deloitte LLP

 

Auditor:

Deloitte LLP

 

Auditor History

Deloitte LLP

30-Nov-2012

Deloitte LLP

30-Nov-2011

Deloitte LLP

30-Nov-2010

Deloitte LLP

30-Nov-2009

Deloitte LLP

30-Nov-2008

 

 

 

GBP(mil)

Audit Fees:

0.0

Non Audit Fees:

0.0

Audit Fiscal Year:

11-30-2012

 

 

 

 

 

 


 

Corporate Family

Corporate Structure News:

 

Cbpe Capital LLP
Idis Ltd.

Idis Ltd. 
Total Corporate Family Members: 46 

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

 

Cbpe Capital LLP

Parent

London

United Kingdom

Pensions and Funds

20.9

26

 

Cote Restaurants Ltd.

Subsidiary

London

United Kingdom

Restaurants and Bars

77.9

1,124

 

Recently acquired (previously owned by Cote Restaurants Ltd.).See corporate structure news on Cbpe Capital LLP for details

Equiniti X2 Ltd.

Subsidiary

Crawley

United Kingdom

Miscellaneous Professional Services

 

1,000

 

Equiniti X2 Solutions Ltd.

Subsidiary

Crawley

United Kingdom

Holding Companies

 

 

 

Equiniti X2 Cap Ltd.

Subsidiary

Crawley

United Kingdom

Miscellaneous Professional Services

 

 

 

Equiniti X2 Services Ltd.

Subsidiary

Crawley

United Kingdom

Holding Companies

 

1,000

 

Equiniti Services Ltd.

Subsidiary

Reading

United Kingdom

Miscellaneous Professional Services

 

45

 

Paymaster (1836) Ltd.

Subsidiary

Crawley

United Kingdom

Miscellaneous Professional Services

185.3

792

 

Xafinity Consulting Ltd.

Subsidiary

Leeds

United Kingdom

Consulting Services

63.0

330

 

Hr Trustees Ltd.

Subsidiary

Reading

United Kingdom

Banking

3.8

 

 

Xafinity Pt Ltd.

Subsidiary

Reading

United Kingdom

Life and Health Insurance

0.1

 

 

Entegria Ltd.

Subsidiary

Reading

United Kingdom

Consulting Services

 

 

 

Claybrook Computing (Holdings) Ltd.

Subsidiary

Crawley

United Kingdom

Pensions and Funds

 

 

 

Claybrook Computing Ltd.

Subsidiary

Crawley

United Kingdom

Banking

24.7

107

 

Equiniti Software Ltd.

Subsidiary

Crawley

United Kingdom

Pensions and Funds

 

 

 

Equiniti Solutions Ltd.

Subsidiary

Crawley

United Kingdom

Miscellaneous Professional Services

77.5

 

 

Informationlog. Com Ltd.

Subsidiary

Crawley

United Kingdom

 

 

 

 

Cbpe Feeder Partnership (Gp) Ltd.

Subsidiary

London

United Kingdom

Miscellaneous Professional Services

0.0

 

 

Cbpe Nominees Ltd.

Subsidiary

London

United Kingdom

Pensions and Funds

 

 

 

Away Resorts Holdings Ltd.

Subsidiary

Hemel Hempstead

United Kingdom

Hotels and Accommodation

23.7

244

 

Away Resorts Ltd.

Subsidiary

Hemel Hempstead

United Kingdom

Hotels and Accommodation

1.6

11

 

Mill Rythe Ltd.

Subsidiary

Hemel Hempstead

United Kingdom

Hotels and Accommodation

7.3

120

 

Whitecliff Bay Holiday Park Ltd.

Subsidiary

Bembridge

United Kingdom

Hotels and Accommodation

7.1

63

 

Whitecliff Bay And Hotel Co., Ltd.

Subsidiary

Hemel Hempstead

United Kingdom

Hotels and Accommodation

 

 

 

Tattershall Lakes Ltd.

Subsidiary

Hemel Hempstead

United Kingdom

Hotels and Accommodation

9.2

58

 

Away Resorts (Transport) Ltd.

Subsidiary

Hemel Hempstead

United Kingdom

Shipping and Water Transport

0.6

 

 

Idis Group Holdings Ltd.

Subsidiary

Weybridge

United Kingdom

Health and Personal Care Wholesale

230.0

180

 

Idis Group Ltd.

Subsidiary

Weybridge

United Kingdom

Miscellaneous Professional Services

 

 

 

Idis Ltd.

Subsidiary

Weybridge

United Kingdom

Health and Personal Care Wholesale

228.6

180

 

Idis Trustee (Uk) Ltd.

Subsidiary

Weybridge

United Kingdom

Nonclassifiable Establishments

 

 

 

Cbpe Trustees Ltd.

Subsidiary

London

United Kingdom

Pensions and Funds

 

 

 

Cbpe Founders Ltd.

Subsidiary

London

United Kingdom

Pensions and Funds

 

 

 

Cbpe Holdings Ltd.

Subsidiary

London

United Kingdom

Pensions and Funds

 

 

 

Cbpe Services Ltd.

Subsidiary

London

United Kingdom

Banking

6.2

26

 

Cbpe (General Partner) Ltd.

Subsidiary

London

United Kingdom

Banking

7.4

 

 

Aqualisa Group Ltd

Subsidiary

Westerham

United Kingdom

Miscellaneous Professional Services

54.4

240

 

Aqualisa Finance Ltd

Subsidiary

Westerham

United Kingdom

Holding Companies

54.4

238

 

Aqualisa Products Ltd.

Subsidiary

Westerham

United Kingdom

Metal Products Manufacturing

53.1

232

 

Hydrocast Products Ltd.

Subsidiary

Westerham

United Kingdom

 

 

 

 

Goldsmith Patent (Sevenoaks) Ltd.

Subsidiary

Westerham

United Kingdom

 

 

 

 

Gainsborough Bathroom Products Ltd

Subsidiary

Westerham

United Kingdom

Metal Products Manufacturing

10.7

6

 

Arranco 3 Ltd.

Subsidiary

Aberdeen

United Kingdom

Miscellaneous Professional Services

 

 

 

Cbpe Capital Feeder Fund Gp Ltd.

Subsidiary

Edinburgh

United Kingdom

Pensions and Funds

0.0

 

 

Cbpe Capital Viii Gp Ltd.

Subsidiary

Edinburgh

United Kingdom

Banking

 

 

 

Cbpe Ltd.

Subsidiary

London

United Kingdom

Pensions and Funds

 

 

 

Cbpe Viii Investco Ltd.

Subsidiary

London

United Kingdom

Pensions and Funds

 

 

 

 

 

Executive report

 

 

Board of Directors

 

Name

Title

Function

 

Natalie Douglas

 

Chief Executive Officer

Director/Board Member

 

Soimitra Tony Dutta

 

Director

Director/Board Member

 

Biography:

Tony has over 20 years senior executive experience in the pharmaceutical industry with a specific focus on global operations and commercial relationships. He joined Idis from Schering Plough in 2006 as Operations Director, becoming Managing Director of the European Operation in 2010. Prior to joining Idis, Tony held the position of Head of Supply Chain for UK and Ireland at Schering-Plough before which he was with Bio Products Laboratory for 15 years as Head of Operations.

 

Age: 50

 

Richard James Elliott Holmes

 

Director

Director/Board Member

 

 

Biography:

Richard joined Idis from the UK retail sector as Financial Controller in 2008. He became European Finance Director in 2011 and was appointed Group Finance Director in 2012. Richard qualified as a Chartered Accountant with a Top 20 accountancy firm in the City of London and holds a BA (Hons) degree in Geography from Manchester University.

 

Age: 38

 

 

Executives

 

Name

Title

Function

 

Natalie Douglas

 

Chief Executive Officer

Chief Executive Officer

 

Guy Strutton

 

Global Head of Learning and Development

Training Executive

 

Social: http://www.linkedin.com/img/icon/icon_company_insider_in_12x12.gif

Emma Grant

 

Head of Customer Services

Customer Service Executive

 

 

Mark Ware

 

Global Account Director

Sales Executive

 

 

Nichola Wisener

 

Account Director, European, Asia Pacfic and ROW Group

Sales Executive

 

 

Richard Greatorex

 

Divisional Marketing Director

Marketing Executive

 

 

Social: http://www.linkedin.com/img/icon/icon_company_insider_in_12x12.gif

Rachel Tebbutt

 

Brand Manager

Advertising Executive

 

 

Robin Wyett

 

Facilities Manager

Facilities Executive

 

 

Suzanne Gagnon

 

CHIEF MEDICAL OFFICER;member of the leadership team

Medical Specialist

 

 

Biography:

Dr. Gagnon has more than twenty years of leadership experience in the medical, regulatory and safety aspects of pharmaceutical product development, including senior management positions in both academia and in the pharmaceutical and CRO industries. Formerly she was CMO and Executive Vice President at ICON Clinical Research for nearly ten years, and more recently the CMO at NuPath, Inc. Dr. Gagnon received her medical degree from Boston University School of Medicine with distinction. She performed postgraduate clinical research at the University of Miami School of Medicine, including studies of the treatment of HIV in one of the first NIAID-sponsored AIDS Clinical Trials Groups. She is an international editorial advisor to Elsevier Publishing, the author or co-author of numerous publications, abstracts and book chapters and a frequent international speaker.

 

Simon Estcourt

 

member of the leadership team

Other

 

 

Biography:

Following a senior executive sales career in the pharmaceutical industry, latterly at Servier Laboratories, Simon joined Idis as Business Development Director from Quintiles in 2008. In 2010 he became Senior Vice President, Strategy & Corporate Development, a global role that includes strategy, marketing, public affairs and new service development. Simon has a deep understanding of the environment and international landscape for managed access. He is a regular spokesperson and author on behalf of Idis and regularly speaks at international conferences on the subject of access to medicines.

 

Social: http://www.linkedin.com/img/icon/icon_company_insider_in_12x12.gif

Maxine Hamilton

 

member of the leadership team

Other

 

 

Biography:

Maxine joined Idis in 2005 as UK Customer Services Manager following a career in IT services and the recruitment industry. Growing with the company, she became Head of Sales and Client Services in 2007 and became Head of Program Management, Managed Access Division in 2009, leading the existing service platform developing a globalizing operation in order to support the increasing needs of our pharmaceutical and biotechnology clients. An industry expert in developing, managing and implementing global managed access programs and solutions to meet the critical needs of patients around the world, Maxine became Divisional Vice President, Managed Access Programs, in 2011.

 

Charles Hart Simmons

 

member of the leadership team

Other

 

 

Biography:

Charles is a distinguished leader, strategist, and negotiator with a proven track record of leading and closing large scale global transactions. He was previously Senior VP, Corporate Development at Mars Inc., prior to which he spent 11 years with Bristol Myers Squibb, where as VP, Corporate Development, he was integral in the various transactions that transformed BMS from a broad based healthcare and consumer company into a BioPharmaceutical business. As President of the Established Brands division, Charles is responsible for developing innovative partnerships with pharmaceutical and biotech companies to enable continued patient access to their marketed products throughout the world. Charles holds a BA from Tufts University and a JD from Pace University. He and his family currently live in McLean, VA.

 

Directors and Shareholders Report

 

Main Office Address:
Idis House Churchfield Road
Weybridge
United Kingdom KT13 8DB

Tel: 01932824000
Fax: 01932824200
URL:http://www.idispharma.com

Annual Return Date: 31 May 2013
Total Issued Capital (GBP 000): 250

 

Individual Directors


Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Soimitra Tony 
Dutta

Current

05 Apr 1963

Idis House Churchfield Road, Weybridge, 
Weybridge, Surrey KT13 8DB

13 Apr 2007

NA

Current:3
Previous:0
Disqualifications:0

 

Richard James Elliott 
Holmes

Current

05 Apr 1975

Idis House Churchfield Road, 
Weybridge, Surrey KT13 8DB

26 Jan 2012

NA

Current:4
Previous:0
Disqualifications:0

 

Natalie Jane 
Douglas

Previous

17 Aug 1966

9 Feltham Avenue, 
West Molesey, Surrey KT8 9BJ

01 Oct 2001

18 Mar 2013

Current:0
Previous:8
Disqualifications:0

 

Michael Arthur William 
Crane

Previous

21 Jun 1945

19 Cumberland Drive, Hinchley Wood, 
Esher, Surrey KT10 0BG

31 May 1991

02 Sep 2005

Current:0
Previous:2
Disqualifications:0

 

Amanda Jane
Gould

Previous

11 Apr 1959

44 Inner Park Road, 
Wimbledon, London SW19 6DD

31 May 1991

02 Sep 2005

Current:1
Previous:1
Disqualifications:0

 

Nicholas Terence 
Butcher

Previous

24 Feb 1947

Moorcroft Abinger Lane, Abinger Common, 
Dorking, Surrey RH5 6HZ

27 Jun 2005

13 Apr 2009

Current:3
Previous:13
Disqualifications:0

 

Gary James 
Mccutcheon

Previous

27 Nov 1959

Eversheds House 70 Great Bridgewater Street, 
Manchester, Greater Manchester M1 5ES

02 Jul 2007

15 Mar 2010

Current:2
Previous:7
Disqualifications:0

 

William Robert 
Doe

Previous

07 Aug 1962

323 Lauderdale Tower, Barbican, 
London , London EC2Y 8NA

02 Sep 2005

02 Jul 2007

Current:2
Previous:6
Disqualifications:0

 

Caroline Julie
Barrett

Previous

25 Dec 1963

White Gables, 115A Old Woking Road,
West Byfleet, Surrey KT14 6HY

01 Oct 2001

02 Sep 2005

Current:0
Previous:2
Disqualifications:0

 

Joanne Louise 
Mcintosh

Previous

06 Dec 1965

1 Fernbank Cottages, Clammer Hill Road, 
Haslemere, Surrey GU27 2DY

01 Oct 2001

31 Mar 2003

Current:0
Previous:1
Disqualifications:0

 

Deborah Dawn 
Howard

Previous

24 Nov 1962

37 Holly Road,
Hampton, Middlesex TW12 1QH

01 Oct 2001

18 Oct 2002

Current:0
Previous:1
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Directors


There are no corporate directors for this company.

 

 

Individual Secretaries


Name

Status

DOB

Filed Address

Appointment Date

Resignation Date

Summary of Directorships

 

Natalie Jane 
Douglas

Previous

17 Aug 1966

9 Feltham Avenue, 
West Molesey, Surrey KT8 9BJ

02 Sep 2005

02 Sep 2005

Current:0
Previous:8
Disqualifications:0

 

Michael Arthur William 
Crane

Previous

21 Jun 1945

19 Cumberland Drive, Hinchley Wood, 
Esher, Surrey KT10 0BG

31 May 1991

07 Dec 1998

Current:0
Previous:2
Disqualifications:0

 

Gary James 
Mccutcheon

Previous

27 Nov 1959

Eversheds House 70 Great Bridgewater Street, 
Manchester, Greater Manchester M1 5ES

02 Jul 2007

28 Feb 2010

Current:2
Previous:7
Disqualifications:0

 

William Robert 
Doe

Previous

07 Aug 1962

323 Lauderdale Tower, Barbican, 
London , London EC2Y 8NA

02 Sep 2005

02 Jul 2007

Current:2
Previous:6
Disqualifications:0

 

Caroline Julie
Barrett

Previous

25 Dec 1963

White Gables, 115A Old Woking Road,
West Byfleet, Surrey KT14 6HY

07 Dec 1998

02 Sep 2005

Current:0
Previous:2
Disqualifications:0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate Secretaries


Company Name

Status

Registered Address

Appointment Date

Resignation Date

Eversecretary Limited

Current

Eversheds House, 70 Great Bridgewater Street, 
Manchester, Greater Manchester M1 5ES

01 Mar 2010

NA

 

 

 

 

Individual Shareholders


There are no individual shareholders for this company.

 

 

 

 

 

 

 

 

 

 

Corporate Shareholders


Company Name

Registration Number

Share Details 
(As Reported)

Share Type

# of Shares

Share Price (GBP)

Share Value (GBP)

% of Total Shares

IDIS Group Limited

05268432

7500000 A Ordinary GBP 0.03

A Ordinary

7,500,000

0.03

225,000.00

75.00

IDIS Group Limited

05268432

2500000 B Ordinary GBP 0.03

B Ordinary

2,500,000

0.03

75,000.00

25.00

 

 

 

Annual Profit & Loss

 

Financials in: USD (mil) 

Except for share items (millions) and per share items (actual units)         

 

 

 

30-Nov-2012

30-Nov-2011

30-Nov-2010

30-Nov-2009

30-Nov-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.632945

0.623804

0.645475

0.646269

0.530439

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Turnover (UK)

54.9

-

-

-

-

Turnover (Exports)

173.8

-

-

-

-

Total Turnover

228.6

207.7

184.9

170.4

139.8

Cost of Sales

173.9

156.7

141.8

128.9

100.3

Gross Profit

54.7

51.0

43.1

41.5

39.5

Depreciation

2.0

1.7

1.3

1.0

0.8

Other Expenses

36.0

32.7

24.7

25.7

22.3

Operating Profit

18.6

18.3

-

-

-

Other Income

0.0

0.0

0.1

0.4

0.6

Interest Paid

0.1

0.0

0.0

0.0

0.0

Exceptional Income

0.0

0.0

0.0

0.0

0.0

Discontinued Operations

0.0

0.0

0.0

0.0

0.0

Profit Before Taxes

18.6

18.3

18.5

16.2

17.8

Tax Payable / Credit

4.7

5.8

3.9

4.2

4.3

Extraordinary Items/Debits

0.0

0.0

0.0

0.0

0.0

Dividends

13.5

10.7

0.0

15.2

0.0

Profit After Taxes

0.3

1.8

14.5

-3.2

13.5

Minority Interests (Profit & Loss)

0.0

0.0

0.0

0.0

0.0

Audit Fees

0.1

0.1

0.1

0.1

0.1

Non Audit Fees

0.1

0.1

0.0

0.0

0.1

Number of Employees

180

140

143

134

124

Wages

13.3

11.8

8.9

9.5

8.9

Social Security Costs

1.4

1.7

1.0

0.9

1.0

Pensions

0.1

0.0

0.1

0.1

0.1

Other Pension Costs

0.6

0.3

0.5

0.5

0.4

Employees Remuneration

15.4

13.8

10.3

10.9

10.3

Directors Emoluments

0.9

0.8

0.8

1.2

1.3

Other Costs

0.0

0.0

0.3

0.0

0.0

Directors Remuneration

0.9

0.8

1.2

1.3

1.4

Highest Paid Director

0.7

0.8

0.4

0.7

0.6

 

 

Annual Balance Sheet

Financials in: USD (mil)

 

 

 

30-Nov-2012

30-Nov-2011

30-Nov-2010

30-Nov-2009

30-Nov-2008

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.624106

0.635809

0.642116

0.609347

0.651699

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Land & Buildings

0.4

0.5

0.5

0.7

0.8

Fixtures & Fittings

6.2

4.4

3.5

3.1

2.3

Plant & Vehicles

0.0

0.0

0.0

0.0

0.0

Total Tangible Fixed Assets

6.6

4.8

4.0

3.8

3.1

Intangible Assets

0.0

0.0

0.0

0.0

0.0

Investments

1.1

1.1

1.1

1.2

1.1

Total Fixed Assets

7.7

5.9

5.1

5.0

4.2

Stocks

7.0

6.6

3.5

3.3

2.7

Work in Progress

0.0

0.0

0.0

0.0

0.0

Total Stocks Work In Progress

7.0

6.6

3.5

3.3

2.7

Trade Debtors

48.9

41.6

34.9

33.3

26.8

Inter-Company Debtors

53.6

32.6

17.0

14.0

9.6

Other Debtors

2.4

3.2

2.6

1.5

4.9

Total Debtors

104.8

77.4

54.5

48.8

41.3

Cash and Equivalents

10.9

11.4

12.9

10.2

16.1

Other Current Assets

0.0

0.0

0.0

0.0

0.0

Total Current Assets

122.7

95.4

70.8

62.3

60.1

Total Assets

130.4

101.3

75.9

67.3

64.3

Trade Creditors

43.5

35.5

20.9

24.9

27.0

Bank Overdraft

0.0

0.0

-

-

-

Inter-Company Creditors

27.2

11.7

0.0

0.9

0.3

Director Loans (Current Liability)

0.0

0.0

-

-

-

Hire Purchase (Current Liability)

0.0

0.0

-

-

-

Finance Lease (Current Liability)

0.0

0.0

-

-

-

Total Finance Lease/Hire Purchase (Current Liability)

0.0

0.0

-

-

-

Total Short Term Loans

0.0

0.0

-

-

-

Accruals/Deferred Income (Current Liability)

17.8

13.4

16.6

14.5

8.1

Social Security/VAT

0.0

0.0

0.3

1.3

1.1

Corporation Tax

2.1

2.1

1.6

2.8

3.1

Dividends (Current Liability)

0.0

0.0

-

-

-

Other Current Liabilities

0.0

0.0

0.1

0.0

0.0

Total Current Liabilities

90.6

62.7

39.5

44.3

39.7

Group Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Director Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Hire Purchase (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Leasing (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Total Hire Purchase Loans (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Other Long Term Loans

0.0

0.0

0.0

0.0

0.0

Accruals/Deferred Income (Long Term Liability)

0.0

0.0

0.0

0.0

0.0

Other Long Term Liabilities

0.0

0.0

0.0

0.0

0.0

Total Long Term Liabilities

0.0

0.0

0.0

0.0

0.0

Deferred Taxation

0.0

0.0

0.0

0.0

0.0

Other Provisions

0.0

0.0

0.0

0.0

0.0

Total Provisions

0.0

0.0

0.0

0.0

0.0

Issued Capital

0.4

0.4

0.4

0.4

0.4

Share Premium Accounts

0.0

0.0

0.0

0.0

0.0

Revaluation Reserve

0.0

0.0

0.0

0.0

0.0

Retained Earnings

39.4

38.2

36.0

22.6

24.2

Other Reserves

0.0

0.0

0.0

0.0

0.0

Minority Interests (Balance Sheet)

0.0

0.0

0.0

0.0

0.0

Total Shareholders Funds

39.8

38.6

36.4

23.0

24.6

Net Worth

39.8

38.6

36.4

23.0

24.6

 

 

Annual Cash Flows

Financials in: USD (mil)

 

 

 

30-Nov-2012

30-Nov-2011

30-Nov-2010

30-Nov-2009

30-Nov-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate (Period Average)

0.632945

0.623804

0.645475

0.646269

0.530439

Consolidated

No

No

No

No

No

 

 

 

 

 

 

 

 

Annual Ratios

Financials in: USD (mil)

 

 

 

30-Nov-2012

30-Nov-2011

30-Nov-2010

30-Nov-2009

30-Nov-2008

Period Length

52 Weeks

52 Weeks

52 Weeks

52 Weeks

52 Weeks

Filed Currency

GBP

GBP

GBP

GBP

GBP

Exchange Rate

0.624106

0.635809

0.642116

0.609347

0.651699

Consolidated

No

No

No

No

No

 

 

 

 

 

 

Current Ratio

1.35

1.52

1.79

1.41

1.51

Liquidity Ratio

1.28

1.42

1.70

1.33

1.45

Stock Turnover

33.18

31.07

53.42

54.73

42.80

Credit Period (Days)

76.95

74.58

68.48

67.33

86.02

Working Capital by Sales

13.85%

16.02%

16.84%

9.96%

17.93%

Trade Credit by Debtors

0.89

0.85

0.60

0.75

1.01

Return on Capital

47.30%

46.47%

50.96%

74.52%

58.90%

Return on Assets

14.45%

17.70%

24.44%

25.46%

22.56%

Profit Margin

8.13%

8.80%

9.98%

9.48%

12.74%

Return on Shareholders Funds

47.30%

46.47%

50.96%

74.52%

58.90%

Borrowing Ratio

68.26%

30.40%

0.01%

3.72%

1.05%

Equity Gearing

30.55%

38.09%

47.95%

34.16%

38.30%

Interest Coverage

234.24

11,792.62

16,232.12

537.19

1,831.00

Sales by Tangible Assets

35.25

42.24

46.45

47.18

36.53

Average Remuneration per Employee

0.1

0.1

0.1

0.1

0.1

Profit per Employee

0.1

0.1

0.1

0.1

0.1

Sales per Employee

1.3

1.5

1.3

1.3

0.9

Capital Employed per Employee

0.2

0.3

0.3

0.2

0.2

Tangible Assets per Employee

0.0

0.0

0.0

0.0

0.0

Total Assets per Employee

0.7

0.7

0.5

0.5

0.5

Employee Remuneration by Sales

6.74%

6.63%

5.59%

6.41%

7.40%

Creditor Days (Cost of Sales Based)

89.98

84.37

53.52

66.38

120.58

Creditor Days (Sales Based)

68.46

63.65

41.03

50.21

86.55

 

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.75

UK Pound

1

Rs.99.56

Euro

1

Rs.83.55

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.